Jonathan Leiken - Feb 5, 2023 Form 4 Insider Report for DIEBOLD NIXDORF, Inc (DBD)

Role
EVP, CLO and Secretary
Signature
Jonathan B. Leiken
Stock symbol
DBD
Transactions as of
Feb 5, 2023
Transactions value $
-$6,854
Form type
4
Date filed
2/7/2023, 03:53 PM
Previous filing
Feb 1, 2023
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DBD Common Shares Tax liability -$6.85K -2.69K -1.01% $2.55* 263K Feb 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DBD Non-Qualified Stock Option 21.4K Feb 5, 2023 Common Shares 21.4K $32.33 Direct F3
holding DBD Non-Qualified Stock Option 24.6K Feb 5, 2023 Common Shares 24.6K $27.39 Direct F3
holding DBD Non-Qualified Stock Options 46.9K Feb 5, 2023 Common Shares 46.9K $26.60 Direct F3
holding DBD Non-Qualified Stock Option 24.5K Feb 5, 2023 Common Shares 24.5K $18.75 Direct F4
holding DBD Non-Qualified Stock Option 43.7K Feb 5, 2023 Common Shares 43.7K $4.08 Direct F4
holding DBD Non-Qualified Stock Option 12K Feb 5, 2023 Common Shares 12K $11.96 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld pursuant to exercise of tax withholding right under the 2017 Equity and Performance Incentive Plan - Restricted Share Award
F2 Number includes restricted stock units.
F3 Granted under the 1991 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.
F4 Granted under the 2017 Equity and Performance Incentive Plan; option is generally exercisable in annual increments of 1/3, 1/3, 1/3 beginning one year from the date of grant.